You searched for "AMM"
Strabismus in thyroid eye disease
Pathogenesis Thyroid eye disease (TED) is an auto-immune condition, in the initial phase there is lymphocytic infiltration and oedema of the extraocular muscles with deposition of glycosaminoglycans and hyaluronic acid and adipogenesis, which can lead to an increase in the...Age-related macular degeneration
1 December 2015
| Nana Theodorou
|
EYE - Vitreo-Retinal
This review article offers an up to date review of the genetic and environmental risk factors associated with aetiology surrounding age-related macular degeneration (AMD). The article briefly describes the typical clinical presentation relating to early and late stages of the...
My top five: Emerging alternatives to manage and treat nAMD
3 April 2024
| Nikhil Sharma, Paras Agarwal
|
EYE - Vitreo-Retinal
Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...
My Top Five: Emerging alternatives to manage and treat nAMD
3 April 2024
| Nikhil Sharma, Paras Agarwal
|
EYE - General
Wet (exudative or neovascular) age-related macular degeneration (AMD) is characterised by choroidal neovascularisation, in which new blood vessels from the choroid invade through Bruch’s membrane. These blood vessels proliferate beneath or through the retinal pigment epithelium (RPE), causing patients to...
Stereotactic radiotherapy for polypoidal choroidal vasculopathy
1 August 2015
| Sofia Rokerya
|
EYE - Vitreo-Retinal
Polypoidal choroidal vasculopathy (PCV) is a variant of neovascular AMD. It is a disease of choroidal vasculature characterised by abnormal branching vascular network with aneurysmal dilatations (polyps). Features of PCV include pigment epithelial detachments (PED), subretinal fluid (SRF) accumulation and...
Four year outcomes of macular degeneration treated with ranibizumab
1 February 2014
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...
Bimedial resection surgery dose-response
The purpose of this study was to evaluate the dose-response relationship for primary bilateral medial rectus (MR) resection in 49 children with exotropia. Fifty-seven percent of children were male and mean age at surgery was 6.7 ±5.3 years. Mean preoperative...Pegcetacoplan: A breakthrough treatment for dry age-related macular degeneration?
Age-related macular degeneration (AMD) is a degenerative condition affecting the macula, the part of the retina responsible for central vision. It is characterised by the presence of drusen and retinal pigment epithelium (RPE) abnormalities in the absence of other macular...Features of AMD treatment non-responders
1 October 2019
| Jonathan Chan
|
EYE - Vitreo-Retinal
This is a retrospective consecutive case series of 365 eyes with age-related macular degeneration (AMD) who had three monthly intravitreal aflibercept treatments for at least 12 months. Responders were defined as complete resolution of exudation, intraretinal oedema, subretinal fluid, pigment...
Characteristics of Charles Bonnet syndrome in patients with neovascular AMD
7 April 2021
| Ed Rule
|
EYE - Vitreo-Retinal
|
Age-related macular degeneration, Charles Bonnet syndrome, Low vision, Negative outcome, Visual hallucinations
This retrospective cross-sectional study aimed to characterise various aspects of Charles Bonnet syndrome hallucinations among patients with neovascular age-related macular degeneration (AMD). Five hundred and ten consecutive patients were asked a screening question to determine if they had ever suffered...
Initiatives in macular service provision
1 December 2015
| Rod McNeil
|
EYE - Vitreo-Retinal
A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...